Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A

US11358947B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11358947-B2
Application numberUS-201816606200-A
CountryUS
Kind codeB2
Filing dateApr 17, 2018
Priority dateApr 17, 2017
Publication dateJun 14, 2022
Grant dateJun 14, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca 2+ -activated CI″ channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound having one of the following structures (I-5), (I-6) or (I′-6) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein: R 1 is optionally substituted C 1 -C 6 alkylene or optionally substituted heteroalkylene; each R 2 is the same or different and independently hydrogen, methyl, ethyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxy; and R 3 is C 1 -C 6 haloalkyl having at least two different halogens. 2. The compound of claim 1 , having one of the following structures (I-7), (I-8) or (I′-8): wherein: each R 2 is independently H, methyl, ethyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxy; and R 3 is C 1 -C 6 haloalkyl having at least two different halogens. 3. The compound of claim 1 being: 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2,2-Difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; or 2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide. 4. The compound of claim 1 wherein R 2 is H, methyl, ethyl, trifluoromethyl, or trifluoromethoxy. 5. The compound of claim 4 , wherein R 3 is perhaloalkyl. 6. The compound of claim 5 wherein R 3 is chlorodifluoromethyl, bromodifluoromethyl, or difluoroiodomethyl. 7. A pharmaceutical composition comprising a physiologically acceptable excipient and a compound of claim 1 . 8. The pharmaceutical composition of claim 7 wherein the compound of Formula (I) is: 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2,2-Difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; or 2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide. 9. A compound selected from the group consisting of: 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide; and 2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • condensed with rings other than six-membered or with ring systems containing such rings · CPC title

  • C07D333/80Primary

    Seven-membered rings · CPC title

  • C07D333/68Primary

    Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

  • Ortho-condensed systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11358947B2 cover?
Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca 2+ -activated CI″ channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and othe…
Who is the assignee on this patent?
Univ California, Anderson Marc O
What technology area does this patent fall under?
Primary CPC classification C07D333/80. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).